Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells.

PloS one - 1 Jan 2020

Baykal-Köse Seda, Acikgoz Eda, Yavuz Ahmet Sinan, Gönül Geyik Öykü, Ateş Halil, Sezerman Osman Uğur, Özsan Güner Hayri, Yüce Zeynep

Abstract excerpt

Tyrosine kinase inhibitor (TKI) resistance is a major problem in chronic myeloid leukemia (CML). We generated a TKI-resistant K562 sub-population, K562-IR, under selective imatinib-mesylate pressure. K562-IR cells are CD34-/CD38-, BCR-Abl-independent, proliferate slowly, highly adherent and form intact tumor spheroids. Loss of CD45 and other hematopoietic markers reveal these cells have diverged from their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3T3 Cells
Share to Cadherins
Share to Epithelial-Mesenchymal Transition

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to K562 Cells

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Protein Domains

Source

Open in PubMed Open full text

Identifiers

PMID: 32106243
DOI: 10.1371/journal.pone.0229104
PMCID: PMC7046262

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells.PMID 32106243Read ↗

Phenotypic and functional characterization of subpopulation of Imatinib resistant chronic myeloid leukemia cell line.Semantic proximity Read ↗

Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.Semantic proximity Read ↗

Phenotypically plastic drug-resistant chronic myeloid leukaemia cell line displays enhanced cellular dynamics in a zebrafish xenograft model.Semantic proximity Read ↗

Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.Semantic proximity Read ↗

Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.Semantic proximity Read ↗

Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.Semantic proximity Read ↗

Upregulation of Genetic Markers of Poor Prognosis following Chemotherapy in Acute Myeloid Leukemia CellsSemantic proximity Read ↗

Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylateSemantic proximity Read ↗

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications.Semantic proximity Read ↗

Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors.Semantic proximity Read ↗

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34− cell population with intrinsic resistance to imatinibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.